ViiV have agreed to enable generic production of long acting PrEP to 90 countries.

ViiV and the Medicines Patent Pool have enabled access to generic formulation of long acting Cabotegravir for PrEP to 90 low- and lower-middle income countries.

This comes as progress in the global HIV response has slowed, and a rise in infections in many countries has been identified.

UNAIDS Deputy Executive a.i. Dr Matthew Kavanagh said;

“We urge all companies developing long-acting HIV medicines to commit to sharing technology through the Medicines Patent Pool, and all governments to act rapidly to secure affordable access to the newest technologies for all who would benefit from them. There must be no repeat by any company of the deadly delays in rolling out HIV products that we saw early on in the AIDS epidemic and that has recently been repeated with COVID-19 vaccines and therapeutics. Sharing technology is essential for stopping pandemics.”

Read the full announcement on the UNAIDS site here.